These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 29650800)
1. MGUS, lymphoplasmacytic malignancies, and Gaucher disease: the significance of the clinical association. Weinreb NJ; Mistry PK; Rosenbloom BE; Dhodapkar MV Blood; 2018 May; 131(22):2500-2501. PubMed ID: 29650800 [No Abstract] [Full Text] [Related]
2. Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry. Rosenbloom BE; Cappellini MD; Weinreb NJ; Dragosky M; Revel-Vilk S; Batista JL; Sekulic D; Mistry PK Am J Hematol; 2022 Oct; 97(10):1337-1347. PubMed ID: 36054609 [TBL] [Abstract][Full Text] [Related]
3. Gaucher disease prevalence in 600 patients affected by monoclonal gammopathy of undetermined significance. Giuffrida G; Markovic U; Condorelli A; Duminuco A; Calafiore V; Conticello C; Romano A; Grasso S; Riccobene C; Ragusa MTV; Esposito B; Nicolosi D; Calagna M; Nardo A; Consoli U; Uccello G; Di Giacomo V; Neri S; Cingari MR; Rodà F; Innao V; Fiumara A; Duro G; Zizzo C; Di Raimondo F Eur J Haematol; 2023 Dec; 111(6):922-929. PubMed ID: 37747757 [TBL] [Abstract][Full Text] [Related]
4. Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review. Kaur J; Valisekka SS; Hameed M; Bandi PS; Varma S; Onwughalu CJ; Ibrahim H; Mongia H Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):e195-e212. PubMed ID: 36966041 [TBL] [Abstract][Full Text] [Related]
5. [Monoclonal gammopathy of undetermined significance and multiple myeloma]. Schmalzing M; Tony HP; Knop S Z Rheumatol; 2017 Oct; 76(Suppl 2):33-37. PubMed ID: 29330758 [TBL] [Abstract][Full Text] [Related]
7. Monoclonal gammopathy of undetermined significance (MGUS) manifestation in CNS: a regular or chance occurrence? Prakhova L; Lebedev V; Ilves A; Nazinkina Y BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33762271 [TBL] [Abstract][Full Text] [Related]
8. Outcomes of screening for gammopathies in children and adults with Gaucher disease type 1 in a cohort from Brazil and the United States. Abell K; Chadwell SE; Burrow TA; Becker APP; Bailey L; Steele P; Zhang X; Islas-Ohlmayer M; Bittencourt R; Schwartz IVD; Prada CE Am J Med Genet C Semin Med Genet; 2020 Dec; 184(4):1052-1059. PubMed ID: 33277783 [TBL] [Abstract][Full Text] [Related]
9. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Leung N; Bridoux F; Hutchison CA; Nasr SH; Cockwell P; Fermand JP; Dispenzieri A; Song KW; Kyle RA; Blood; 2012 Nov; 120(22):4292-5. PubMed ID: 23047823 [TBL] [Abstract][Full Text] [Related]
10. A bone paradigm challenging the standard model of myeloma oncogenesis. Capp JP; Bataille R Crit Rev Oncol Hematol; 2022 Apr; 172():103640. PubMed ID: 35183697 [TBL] [Abstract][Full Text] [Related]
11. Progression from Monoclonal gammopathy of undetermined significance of the immunoglobulin M class (IgM-MGUS) to Waldenstrom Macroglobulinemia is associated with an alteration in lipid metabolism. Jalali S; Shi J; Ahsan N; Wellik L; Serres M; Buko A; Paludo J; Kim H; Tang X; Yang ZZ; Novak A; Kyle R; Ansell S Redox Biol; 2021 May; 41():101927. PubMed ID: 33690107 [TBL] [Abstract][Full Text] [Related]
12. Towards a better understanding of monoclonal gammopathy of renal significance. Bianchi G; Richardson PG Br J Haematol; 2019 Sep; 186(5):653-654. PubMed ID: 31134621 [No Abstract] [Full Text] [Related]
14. [Long-term follow-up of monoclonal gammopathies of undetermined significance (MGUS)]. Goldschmidt H; Nitschmann S Internist (Berl); 2018 Jun; 59(6):639-640. PubMed ID: 29696302 [No Abstract] [Full Text] [Related]
15. IgM monoclonal component associated with type I Gaucher disease resolved after enzyme replacement therapy: a case report. Martinez-Redondo C; Ortuño FJ; Lozano ML; Jerez A; del Mar Osma M; Giraldo P; Vicente V J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S265-7. PubMed ID: 19562501 [TBL] [Abstract][Full Text] [Related]
16. [Monoclonal gammopathy of undetermined significance and evolution to myeloma: Experience in 153 patients]. López Gómez JM; Sacristán Enciso B; Fernández-Cavada Pollo MJ; Bueno García V; Gómez Vera S Semergen; 2021 Oct; 47(7):441-447. PubMed ID: 34479794 [TBL] [Abstract][Full Text] [Related]
18. Acquired von willebrand syndrome secondary to monoclonal gammopathy of undetermined significance: long-term remission after treatment with bortezomib. Saldanha A; Veiga ME; Okazaki E; Rothschild C; Martinez G; Rocha V; Orsi FA; Villaca P J Thromb Thrombolysis; 2023 May; 55(4):770-774. PubMed ID: 37000318 [TBL] [Abstract][Full Text] [Related]
19. Autoimmunity, Infections, and the Risk of Monoclonal Gammopathy of Undetermined Significance. Sigurbergsdóttir AÝ; Love TJ; Kristinsson SY Front Immunol; 2022; 13():876271. PubMed ID: 35572590 [TBL] [Abstract][Full Text] [Related]
20. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis. Go RS; Gundrum JD; Neuner JM Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):177-186.e4. PubMed ID: 25445471 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]